Clinical Case Series - 26aml - Question 2

In your clinical practice, how do you typically manage QTc prolongation that develops during menin-inhibitor therapy for relapsed AML?

Hold therapy immediately and permanently discontinue the suspected agent

Hold therapy, address reversible factors (e.g., electrolytes, interacting medications), then reassess QTc before deciding on dose modifications or resumption

Continue therapy without changes unless QTc exceeds 520 ms

Transition the patient to supportive care

Unsure

{"name":"Clinical Case Series - 26aml - Question 2", "url":"https://www.poll-maker.com/QJFIYK70U","txt":"In your clinical practice, how do you typically manage QTc prolongation that develops during menin-inhibitor therapy for relapsed AML?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}

Tools: Poll Maker | Quiz Maker